首页> 外文期刊>Vaccine >Generation of a live rabies vaccine strain attenuated by multiple mutations and evaluation of its safety and efficacy
【24h】

Generation of a live rabies vaccine strain attenuated by multiple mutations and evaluation of its safety and efficacy

机译:狂犬病活疫苗株的多重突变减毒及其安全性和有效性评估

获取原文
获取原文并翻译 | 示例
           

摘要

An amino acid substitution at position 333 in rabies virus G protein is known to determine the pathogenicity: strains with Arg or Lys at that position kill adult mice after intracerebral inoculation, whereas strains with other amino acids cause non-lethal infection. Based on those findings, attenuated rabies virus strains have been established and used for oral vaccines mainly for wild animals. However, considering the possibility of back-mutation to the virulent phenotype, a strain that is attenuated by multiple mutations not only in the G protein but also in other viral proteins would be more appropriate as a safe live vaccine. We previously demonstrated that the fixed rabies virus Ni-CE strain, which causes only transient body weight loss in adult mice after intracerebral inoculation, is mainly attenuated by mutations in the N, P and M proteins, while this strain has virulent-type Arg at position 333 in the G protein. In this study, to obtain a live vaccine strain that is attenuated by multiple mutations, we generated Ni-CE mutant, Ni-CE(G333Glu) strain, which has an Arg-to-Glu mutation at position 333 in the G protein, and examined its pathogenicity and immunogenicity. We found that, in contrast to Ni-CE strain, Ni-CE(G333Glu) strain did not cause transient body weight loss in adult mice after intracerebral inoculation. The attenuated phenotype of Ni-CE(G333Glu) strain did not change even after 10 serial intracerebral passages in suckling mice. We also demonstrated that inoculation of Ni-CE(G333Glu) strain induced virus-neutralizing antibody in immunized mice and protected the mice from lethal challenge. These results indicate that Ni-CE(G333Glu) strain is a promising candidate for development of a live rabies vaccine with a high safety level. (C) 2012 Elsevier Ltd. All rights reserved.
机译:已知狂犬病毒G蛋白中333位的氨基酸取代可确定其致病性:在脑内接种后,在该位置带有Arg或Lys的品系会杀死成年小鼠,而具有其他氨基酸的品系会引起非致死性感染。基于这些发现,已经建立了减毒狂犬病毒株并将其用于主要用于野生动物的口服疫苗。但是,考虑到可能会回复突变为强毒表型,因此不仅可以在G蛋白中而且在其他病毒蛋白中被多种突变减毒的菌株更适合作为安全的活疫苗。我们先前证明,固定的狂犬病病毒Ni-CE株仅在成年小鼠脑内接种后引起短暂的体重减轻,主要被N,P和M蛋白的突变所减弱,而该株在60℃时具有强毒型Arg。 G蛋白中的333位。在这项研究中,为了获得被多个突变减弱的活疫苗株,我们生成了Ni-CE突变株Ni-CE(G333Glu)株,其在G蛋白的333位具有Arg-to-Glu突变,并且检查了它的致病性和免疫原性。我们发现,与Ni-CE株相比,Ni-CE(G333Glu)株在脑内接种后不会引起成年小鼠的瞬时体重减轻。 Ni-CE(G333Glu)菌株的减毒表型即使在哺乳小鼠中连续10次脑内传代后也没有改变。我们还证明了接种Ni-CE(G333Glu)株在免疫小鼠中诱导了病毒中和抗体,并保护了小鼠免受致命的攻击。这些结果表明,Ni-CE(G333Glu)菌株是开发具有高安全水平的狂犬病活疫苗的有希望的候选者。 (C)2012 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号